Clinical Trial Detail

NCT ID NCT04099641
Title An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Oncologie Inc.
Indications

gastric adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Bavituximab + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.